+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 23 Pages
  • July 2023
  • GlobalData
  • ID: 4429756
Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions
  • Corporate strategy - The publisher's summarization of the company’s business strategy
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats
  • Company history - Progression of key events associated with the company
  • Major products and services - A list of major products, services and brands of the company
  • Key competitors - A list of key competitors to the company
  • Key employees - A list of the key executives of the company
  • Executive biographies - A brief summary of the executives’ employment history
  • Key operational heads - A list of personnel heading key departments/functions
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details

Highlights

Urigen Pharmaceuticals Inc (Urigen) is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on the development of products for symptoms associated with urological ailments and painful bladder syndrome (PBS). Its pipeline products include URG101 and URG501, intended for the treatment of interstitial cystitis and bladder pain syndrome. It also focuses on the development of URG 801, which is in the preclinical stage for the treatment of Hunner’s lesions of severe interstitial cystitis and bladder pain syndrome. Urigen is headquartered in Bound Brook, New Jersey, the US.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Urigen Pharmaceuticals Inc - Key Facts
  • Urigen Pharmaceuticals Inc - Key Employees
  • Urigen Pharmaceuticals Inc - Key Employee Biographies
  • Urigen Pharmaceuticals Inc - Major Products and Services
  • Urigen Pharmaceuticals Inc - History
  • Urigen Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Urigen Pharmaceuticals Inc - Business Description
  • Urigen Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Urigen Pharmaceuticals Inc - Strengths
  • Urigen Pharmaceuticals Inc - Weaknesses
  • Urigen Pharmaceuticals Inc - Opportunities
  • Urigen Pharmaceuticals Inc - Threats
  • Urigen Pharmaceuticals Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Urigen Pharmaceuticals Inc, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Urigen Pharmaceuticals Inc, Key Facts
  • Urigen Pharmaceuticals Inc, Key Employees
  • Urigen Pharmaceuticals Inc, Key Employee Biographies
  • Urigen Pharmaceuticals Inc, Major Products and Services
  • Urigen Pharmaceuticals Inc, History
  • Urigen Pharmaceuticals Inc, Key Competitors
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Urigen Pharmaceuticals Inc, Recent Deals Summary
List of Figures
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Janssen Pharmaceuticals Inc
  • rEVO Biologics Inc
  • Mission Pharmacal Co
  • Plethora Solutions Holdings Plc
  • Halozyme Therapeutics Inc